Trial Profile
A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Vonicog alfa (Primary) ; Factor VIII; Octocog alfa
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Acronyms rVWF IN PROPHYLAXIS
- Sponsors Baxalta; Shire; Takeda
- 19 Apr 2022 Results assessing efficacy and safety of Recombinant von Willebrand factor prophylaxis in adults with severe von Willebrand disease published in the Blood
- 14 Dec 2021 Data from four studies ((NCT00816660; NCT01410227; NCT02283268; NCT02973087) used to the exposure-response (ER) relationship between VWF activity (measured by VWF:ristocetin cofactor [RCo]), endogenous factor VIII (FVIII) activity (measured by FVIII:C), and spontaneous bleeding events (sBEs) in patients with severe VWD receiving rVWF prophylaxis for up to 1 year presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 20 Jul 2021 According to a Takeda media release, results from this trial were presented at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress 2021.